Bank of New York Mellon Corp increased its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 10.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,521,166 shares of the biotechnology company's stock after buying an additional 147,748 shares during the period. Bank of New York Mellon Corp owned 0.64% of ADMA Biologics worth $26,088,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of ADMA. Hollencrest Capital Management purchased a new stake in ADMA Biologics in the third quarter worth $30,000. Larson Financial Group LLC bought a new position in shares of ADMA Biologics in the 3rd quarter worth about $31,000. GAMMA Investing LLC lifted its position in ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 967 shares during the period. National Bank of Canada FI bought a new stake in ADMA Biologics during the third quarter worth about $35,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in ADMA Biologics in the third quarter worth about $62,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Separately, Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.
View Our Latest Stock Report on ADMA
ADMA Biologics Stock Down 3.2 %
Shares of NASDAQ:ADMA traded down $0.59 during trading on Thursday, reaching $17.92. 1,638,249 shares of the stock traded hands, compared to its average volume of 3,323,650. ADMA Biologics, Inc. has a 52-week low of $5.88 and a 52-week high of $23.64. The stock has a market cap of $4.23 billion, a P/E ratio of 63.98 and a beta of 0.60. The stock has a 50-day moving average of $16.67 and a two-hundred day moving average of $17.95. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Further Reading
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
